Literature DB >> 11792737

Evolution of anticancer drug discovery and the role of cell-based screening.

Frank M Balis.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 11792737     DOI： 10.1093/jnci/94.2.78

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  18 in total

Review 1.  Modeling tissue-specific signaling and organ function in three dimensions.

Authors:  Karen L Schmeichel; Mina J Bissell
Journal:  J Cell Sci       Date:  2003-06-15       Impact factor: 5.285

2.  Modelling tissues in 3D: the next future of pharmaco-toxicology and food research?

Authors:  Giovanna Mazzoleni; D Di Lorenzo; N Steimberg
Journal:  Genes Nutr       Date:  2008-12-18       Impact factor: 5.523

Review 3.  The oxidative stress theory of disease: levels of evidence and epistemological aspects.

Authors:  Pietro Ghezzi; Vincent Jaquet; Fabrizio Marcucci; Harald H H W Schmidt
Journal:  Br J Pharmacol       Date:  2016-08-04       Impact factor: 8.739

Review 4.  Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression.

Authors:  Mina J Bissell; William C Hines
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

Review 5.  The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval.

Authors:  Mariana Matias; Jacinta O Pinho; Maria João Penetra; Gonçalo Campos; Catarina Pinto Reis; Maria Manuela Gaspar
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

6.  Human skin equivalent as an alternative to animal testing.

Authors:  Heike Mertsching; Michaela Weimer; Silke Kersen; Herwig Brunner
Journal:  GMS Krankenhhyg Interdiszip       Date:  2008-03-11

Review 7.  Miniaturized pre-clinical cancer models as research and diagnostic tools.

Authors:  Maria Håkanson; Edna Cukierman; Mirren Charnley
Journal:  Adv Drug Deliv Rev       Date:  2013-12-01       Impact factor: 15.470

8.  Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine.

Authors:  Shigeyuki Matsui; Richard Simon; Pingping Qu; John D Shaughnessy; Bart Barlogie; John Crowley
Journal:  Clin Cancer Res       Date:  2012-08-27       Impact factor: 12.531

9.  Utilization of genomic signatures to identify phenotype-specific drugs.

Authors:  Seiichi Mori; Jeffrey T Chang; Eran R Andrechek; Anil Potti; Joseph R Nevins
Journal:  PLoS One       Date:  2009-08-28       Impact factor: 3.240

10.  An antitubulin agent BCFMT inhibits proliferation of cancer cells and induces cell death by inhibiting microtubule dynamics.

Authors:  Ankit Rai; Avadhesha Surolia; Dulal Panda
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.